Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)

Baird analyst Joel Beatty reiterated an Outperform rating and $60.00 price target on Longboard Pharmaceuticals Inc (NASDAQ: LBPH).

The analyst commented: "Longboard's investor and analyst event focused on the phase 3 plans for bexicaserin for the treatment of Developmental and Epileptic Encephalopathies (DEEs), and was largely in line with investor expectations, in our view. The phase 3 program is expected to initiate around the end of September, with topline results around YE26. We continue to see meaningful longer-term upside for the stock, because we believe bexicaserin is likely to succeed in phase 3 and sales are likely to exceed $1B/year."

For an analyst ratings summary and ratings history on Longboard Pharmaceuticals Inc click here. For more ratings news on Longboard Pharmaceuticals Inc click here.

Shares of Longboard Pharmaceuticals Inc closed at $30.74 yesterday.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Corporación América Airports signs Brasilia concession amendment
• Revive Therapeutics proposes $1M private placement